Bifunctional [2′,6′-dimethyl-L-tyrosine1] endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed μ-agonist/δ-antagonist and dual μ-agonist/δ-agonist opioid ligands

Journal of Medicinal Chemistry

Volumn 50, Issue 12, 2007, Pages 2753-2766

  Li, Tingyou ^a   Shiotani, Kimitaka ^a   Miyazaki, Anna ^a   Tsuda, Yuko ^a   Ambo, Akihiro ^b   Sasaki, Yusuke ^b   Jinsmaa, Yunden ^c   Marczak, Ewa ^c   Bryant, Sharon D ^c   Lazarus, Lawrence H ^c   Okada, Yoshio ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',6' DIMETHYLTYROSYLPROLYL 2' ETHYL 6' METHYLPHENYLALANYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 2' ISOPROPYL 6' METHYLPHENYLALANYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 2' METHYLPHENYLALANYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 2',4',6' TRIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 2',6' DIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 2',6' DIMETHYLTYROSYLPHENYLALANYLAMIDE; 2',6' DIMETHYLTYROSYLPROLYL 3',5' DIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; ENDOMORPHIN 2; ENDORPHIN DERIVATIVE; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; TYROSYLPROLYL 2' ETHYL 6' METHYLPHENYLALANYLPHENYLALANYLAMIDE; TYROSYLPROLYL 2' ISOPROPYL 6' METHYLPHENYLALANYLPHENYLALANYLAMIDE; TYROSYLPROLYL 2' METHYLPHENYLALANYLPHENYLALANYLAMIDE; TYROSYLPROLYL 2',4',6' TRIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; TYROSYLPROLYL 2',6' DIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; TYROSYLPROLYL 2',6' DIMETHYLTYROSYLPHENYLALANYLAMIDE; TYROSYLPROLYL 3',5' DIMETHYLPHENYLALANYLPHENYLALANYLAMIDE; UNCLASSIFIED DRUG; DELTA OPIATE RECEPTOR; DRUG DERIVATIVE; LIGAND; MU OPIATE RECEPTOR; OLIGOPEPTIDE; TYROSINE;

ALKYLATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IC 50; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR AFFINITY; ANIMAL; BINDING COMPETITION; BRAIN; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; INNERVATION; METABOLISM; MUSCLE CONTRACTION; MYENTERIC PLEXUS; NEUROMUSCULAR SYNAPSE; PHYSIOLOGY; RADIOASSAY; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNAPTOSOME; SYNTHESIS; VAS DEFERENS;

ANIMALS; BINDING, COMPETITIVE; BRAIN; GUINEA PIGS; LIGANDS; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYENTERIC PLEXUS; NEUROMUSCULAR JUNCTION; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES; TYROSINE; VAS DEFERENS;

EID: 34250891407     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061238m     Document Type: Article

References (69)

1. Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A Potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997, 386, 499-502.
2. Wilson, A. M.; Soignier, R. D.; Zadina, J. E.; Kastin, A. J.; Nores, W. L.; Olson, R. D.; Olson, G. A. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 2000, 21, 1871-1874.
3. Carrigan, K. A.; Nelson, C. J.; Lysle, D. T. Endomorphin-1 induces antinociception without immunomodulatory effects in the rat. Psychopharmacology 2000, 151, 299-305.
4. Harrison, L. M.; Kastin, A. J.; Zadina, J. E. Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides 1998, 19, 749-753.
5. 35S] GTPγS binding by endomorphin 1 and DAMGO in mouse brains. Peptides 1998, 19, 755-758.
6. Soignier, R. D.; Vaccarino, A. L.; Brennan, A. M.; Kastin, A. J.; Zadina, J. E. Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice. Life Sci. 2000, 67, 907-912.
7. Chen.; J.-C.; Tao, P.-L.; Li, J.-Y.; Wong, C.-H.; Huang, E. Y.-K. Endomorphin-1 and -2 induced naloxone-precipitated withdrawal syndromes in rats. Peptides 2003, 24, 477-481.
8. Kosson, P.; Bonney, I.; Carr, D. B.; Lipkowski, A. W. Endomorphins interact with tachykinin receptors. Peptides 2005, 26, 1667-1669.
9. 1-7 in the rat spinal cord. Peptides 2006, 27, 753-759.
10. Leitgeb, B.; Szekeres, A.; Tóth, G. Conformational analysis of endomorphin-1 by molecular dynamics methods. J. Peptide Res. 2003, 62, 145-157.
11. Podlogar, B. L.; Paterlini, G.; Ferguson, D. M.; Leo, G. C.; Demeter, D. A.; Brown, F. K.; Reitz, A. B. Conformational analysis of the endogenous μ-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling. FEBS Lett. 1998, 439, 13-20.
12. Fiori, S.; Renner, C.; Cramer, J.; Pegoraro, S.; Moroder, L. Preferred conformation of endomorphin-1 in aqueous and membrane-mimetic environments. J. Mol. Biol. 1999, 291, 163-175.
13. Keller, M.; Boissard, C.; Patiny, L.; Chung, N. N.; Lemieux, C.; Mutter, M.; Schiller, P. W. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis-Tyr-Pro amide bond in the bioactive conformation. J. Med. Chem. 2001, 44, 3896-3903.
14. 1H NMR spectroscopy and molecular modeling calculation. J. Peptide Res. 2001, 58, 399-412.
15. Janecka, A.; Fichna, J.; Kruszynski, R.; Sasaki, Y.; Ambo, A.; Costentin, J.; do-Rego, J.-C. Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs. Biochem. Pharmacol. 2005, 71, 188-195.
16. 2, display partial agonist potency but significant antinociception. Life Sci. 2005, 77, 1155-1165.
17. Cadillo, G.; Gentilucci, L.; Tolomelli, A.; Spinosa, R.; Calienni, M.; Qasen, A.; Spampinato, S. Synthesis and evaluation of the affinity toward μ-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]. J. Med. Chem. 2004, 47, 5198-5203.
18. Tömböly, C.; Kövér, K. E.; Péter, A.; Tourwé, D.; Biyashev, D.; Benyhe, S.; Borsodi, A.; Al-Khrasani, M.; Rónai, A. Z.; Tóth, G. Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J. Med. Chem. 2004, 47, 735-743.
19. Lengyel, I.; Orosz, G.; Biyashev, D.; Kocsis, L.; Al-Khrasani, M.; Rónai, A.; Tömböly, C.; Fürst, Z.; Tóth, G.; Borsodi, A. Side chain modifications change the binding and agonist properties of endomorphin 2. Biochem. Biophys. Res. Commun. 2002, 290, 153-161.
20. Cardillo, G.; Gentilucci, L.; Qasem, A. R.; Sgarzi, F.; Spampinato, S. Endomorphin-1 analogues containing β-proline are μ-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance. J. Med. Chem. 2002, 45, 2571-2578.
21. Wei, J.; Shao, X.; Gong, M.-Z.; Zhu, B.-B.; Cui, Y.-X.; Gao, Y.-F.; Wang, R. Structure-activity relationships of novel endomorphin-2 analogues with N-O turns induced by α-aminoxy acids. Bioorg. Med. Chem. Lett. 2005, 15, 2986-2989.
22. Kruszynski, R.; Fichna, J.; do-Rego, J.-C.; Janecki, T.; Kosson, P.; Pakulska, W.; Costentin, J.; Janecka, A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. Bioorg. Med. Chem. 2005, 13, 6713-6717.
23. (a) Fujita, Y.; Motoyama, T.; Takahashi, M.; Shimizu, Y.; Tsuda, Y.; Yokoi, T.; Li, T.; Sasaki, Y.; Ambo, A.; Kita, A.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Development of potent bifunctional endomorphin-2 analogs with mixed μ-/δ-opioid agonist/ δ-opioid antagonist properties. J. Med. Chem. 2004, 47, 3591-3599.
24. 4]endomorphin-2 is a potent μ-opioid receptor antagonist in the aequorin luminescence-based calcium assay. Life Sci. 2006, 79, 1094-1099.
25. 1] endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg. Med. Chem. 2003, 11, 1983-1994.
26. Gao, Y.-F.; Liu, X.; Wei, J.; Zhu, B.-B.; Chen, Q.; Wang, R. Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg. Med. Chem. Lett. 2005, 15, 1847-1850.
27. Hruby, V. J.; Gehrig, C. A. Recent development in the design of receptor specific opioid peptides. Med. Res. Rev. 1989, 9, 343-401.
28. (a) Bryant, S. D.; Salvadori, S.; Cooper, P. S.; Lazarus, L. H. New δ opioid antagonists as pharmacological probes. Trends Pharmacol. Sci. 1999, 19, 42-46.
29. (b) Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: A potent alliance. Biopolymers 2003, 71, 86-102.
30. (a) Lazarus, L. H.; Bryant, S. D.; Salvadori, S.; Attila, M.; Jones, L. S. Opioid infidelity. Novel opioid agonists with dual high affinities for δ and μ receptors. Trends Neurosci. 1998, 19, 31-35.
31. (b) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
32. 1-benzimidazole alkylation. J. Med. Chem. 2005, 48, 8112-8114.
33. (d) Balboni, G.; Onnis, V.; Salvadori, S.; Zotti, M.; Sasaki, Y.; Ambo, A.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J. Med. Chem. 2006, 49, 5610-5617.
34. Li, T.; Fujita, Y.; Tsuda, Y.; Miyazaki, A.; Ambo, A.; Sasaki, Y.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Development of potent μ-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J. Med. Chem. 2005, 48, 586-592.
35. Sasaki, Y.; Kawano, S.; Kohara, H.; Watanabe, H.; Ambo, A. ORL1 and opioid receptor preferences of nociceptin and dynorphin A analogues with Dmp substituted for N-terminal aromatic residues. Bioorg. Med. Chem. 2006, 14, 2433-2437.
36. Sasaki, Y.; Hirabuki, M.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Enkephalin analogues with 2′,6′-dimethylphenylalanine replacing phenylalanine in position 4. Bioorg. Med. Chem. Lett. 2001, 11, 327-329.
37. Ambo, A.; Murase, H.; Niizuma, H.; Ouchi, H.; Yamamoto, Y.; Sasaki, Y. Dermorphin and deltorphin heptapeptide analogues: replacement of Phe residue by Dmp greatly improves opioid receptor affinity and selectivity. Bioorg. Med. Chem. Lett. 2002, 12, 879-881.
38. Ambo, A.; Niizuma, H.; Sasaki, A.; Kohara, H.; Sasaki, Y. Dermorphin tetrapeptide analogues with 2′,6′-dimethylphenylalanine (Dmp) substituted for aromatic amino acids have high μ opioid receptor binding and biological activities. Bioorg. Med. Chem. Lett. 2003, 13, 1269-1272.
39. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residues as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg. Med. Chem. 2003, 11, 675-678.
40. Sasaki, Y.; Sasaki, A.; Ariizuma, T.; Igari, Y.; Sato, K.; Kohara, H.; Niizuma, H.; Ambo, A. 2′,6′-Dimethylphenylalanine (Dmp) can mimic the N-terminal Tyr in opioid peptides. Biol. Pharm. Bull. 2004, 27, 244-247.
41. 1]jendomorphin- 2-mediated analgesia in the mouse. Eur. J. Pharmacol. 2005, 509, 37-42.
42. 1]jendomorphin-1. Pharmacol. Biochem. Behav. 2006, 84, 252-258.
43. (a) Banks, W. A.; Audus, K. L.; Davis, T. P. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful drugs. Peptides 1992, 13, 1289-1292.
44. (b) Abbruscato, T.; Thomas, S.; Hruby, V.; Davis, T. Blood-brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 1997, 280, 402-409.
45. (c) Egleton, R. D.; Abbruscato, T. J.; Thomas, S. A.; Davis, T. P. Transport of opioid peptides into the central nervous system. J. Pharm. Sci. 1998, 87, 1433-1439.
46. (a) Labarre, M.; Butterworth, J.; St-Onge, S.; Payza, K.; Schmidhammer, H.; Salvadori, S.; Balboni, G.; Guerrini, R.; Bryant, S. D.; Lazarus, L. H. Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. Eur. J. Pharmacol. 2000, 406, R1-R3.
47. (b) Troyen-Tóth, P.; Décaillor, F. M.; Fillol, D.; Lazarus, L. H.; Schiller, P. W.; Schidhammer, H.; Keiffer, B. L. Inverse agonism and neutral antagonism at wild-type and constitutively mutant delta opioid receptors. J. Pharmacol. Exp. Ther. 2005, 313, 410-421.
48. (a) Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
49. (b) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, Y.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
50. Li, T.; Jinsmaa, Y.; Nedachi, M.; Tsuda, Y.; Ambo, A.; Sasaki, Y.; Bryant, S. D.; Marczak, E.; Li, Q.; Swartzwelder, H. S.; Lazarus, L. H.; Okada, Y. Transformation of μ-opioid receptor agonists into biologically potent μ-opioid receptor antagonists. Bioorg. Med. Chem. 2007, 15, 1237-1251.
51. Fundytus, M.; Schiller, P.; Shapiro, M.; Wetrowska, G.; Coderre, T. J. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TTPP[Ψ]. Eur. J. Pharmacol. 1995, 286, 105-108.
52. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 741-743.
53. Li, T.; Tsuda, Y.; Minoura, K.; In, Y.; Ishida, T.; Lazarus, L. H.; Okada, Y. Enantioselective synthesis of a phenylalanine library containing alkyl groups on the aromatic moiety: confirmation of stereostructure by X-ray analysis. Chem. Pharm. Bull. 2006, 54, 873-877.
54. Salvadori, S.; Marastoni, M.; Balboni, G.; Borea, P.; Tomatis, R. Opioid peptides: synthesis and biological properties of dermorphin related hexapeptides. Eur. J. Med. Chem. 1990, 25, 171-177.
55. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ opioid antangonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
56. Gao, Y.-F.; Liu, X.; Liu, W.-X.; Qi, Y.-M.; Liu, X.-F.; Zhou, Y.-F.; Wang, R. Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3 or 4. Bioorg. Med. Chem. Lett. 2006, 16, 3688-3692.
57. Chao, H.; Murray, T. F.; Aldrich, J. V. Synthesis and evaluation of potential affinity labels derived from endomorphin-2. J. Peptide Res. 2003, 61, 58-62.
58. 2 phenotypes. Selective targeting of δ-κ heterodimers. J. Med. Chem. 2004, 47, 2969-2972.
59. (b) Law, P.-Y.; Ericson-Herbandson, L. J.; Zha, Q. Q.; Solberg, J.; Chu, J.; Sarre, A.; Loh, H. H. Heterodimerizaiton of μ- and δ-opioid receptors occurs at the cell surface only and requires receptor-G protein interaction. J. Biol. Chem. 2005, 280, 11152-11164.
60. (c) Snook, L. A.; Milligan, G.; Kieffer, B. L.; Massotte, D. μ-δ opioid receptor functional interaction: insight using receptor-G protein fusions. J. Pharmacol. Exp. Ther. 2006, 318, 683-690.
61. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H. H.; Pintar, J. E.; Devi, L. A. A role of heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5135-5139.
62. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P.-Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 19208-19213.
63. Zhu, Y.; King, M. A.; Schuller, A. G.; Nitsche, J. F.; Reidl, M.; Edle, R. P.; Unterwald, E.; Pasternak, G. W.; Pinter, J. E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron 1999, 24, 243-252.
64. Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303.
65. Bryant, S. D.; Salvadori, S.; Okada, Y.; Takahshi, M.; Sasaki, Y.; Lazarus, L. H. Computational Chemistry and Opioidmimetics: Receptor Ligand Interaction of Three Classes of Biologically Potent Peptides. In Peptide 2000; Martinez, J., Fehrentz, J.-A., Eds., Editions EDK: Paris, 2001; pp 407-408.
66. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3180.
67. 2-NH). Chem. Pharm. Bull. 1995, 43, 1547-1550.
68. 3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur. J. Pharmacol. 1985, 109, 281-284.
69. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.